what is systemic lupus erythematosus

Systemic lupus erythematosus (SLE) is a chronic autoimmune disease in which the immune system mistakenly attacks the body’s own tissues, causing inflammation and damage in multiple organs such as the skin, joints, kidneys, brain, lungs, heart, and blood vessels.

What is systemic lupus erythematosus?

Systemic lupus erythematosus is the most common form of lupus and is classified as a multisystem autoimmune disease, meaning it can affect many organs at once. In SLE, the immune system produces autoantibodies that form immune complexes and deposit in tissues, triggering inflammation and tissue damage. This process can range from mild, episodic symptoms to severe, life‑threatening organ involvement.

How it develops (in simple terms)

• The immune system loses tolerance to “self” and starts recognizing the body’s own DNA and proteins as foreign.

• Abnormal activation of T cells and B cells leads to production of autoantibodies (for example, antinuclear antibodies, or ANA, present in most patients).

• These autoantibodies bind to self‑antigens and form immune complexes that deposit in organs like kidneys, skin, joints, and the brain, causing inflammation.

• Genetic susceptibility, hormones, and environmental triggers (such as infections, ultraviolet light, some drugs) all contribute to disease onset and flares.

Common symptoms and organ involvement

SLE symptoms can be very variable; two people may have very different disease patterns.

Typical features include:

• General: fatigue, fever, weight loss.
• Skin: malar (“butterfly”) rash on the cheeks, photosensitivity, discoid lesions, hair loss, mouth or nose ulcers.
• Joints: joint pain and non‑erosive arthritis, often small joints of the hands.
• Kidneys: lupus nephritis (protein in urine, swelling in legs, high blood pressure, impaired kidney function).
• Blood: anemia, low white cells, low platelets due to autoimmune destruction.
• Heart and lungs: inflammation of the lining (pericarditis, pleuritis), chest pain with breathing.
• Nervous system: headaches, seizures, mood or cognitive changes, neuropathies.
• Vessels and extremities: Raynaud phenomenon (color changes in fingers with cold), vasculitis.

Who is most affected?

• SLE occurs worldwide and affects an estimated few million people globally.

• It predominantly affects women of child‑bearing age, with a strong female‑to‑male predominance.

• Higher rates and often more severe disease are reported in people of African, Hispanic/Latino, Asian, and Indigenous ancestry compared with people of European ancestry.

Diagnosis basics

There is no single “lupus test”; diagnosis is clinical plus lab evidence.

Doctors typically consider:

• Symptom pattern over time (rashes, joint pain, kidney findings, blood count changes, neurologic signs).

• Autoantibodies: antinuclear antibodies (ANA, present in >95% of SLE patients), anti‑dsDNA, anti‑Sm, antiphospholipid antibodies.

• Complement levels and inflammatory markers.

• Classification criteria such as EULAR/ACR 2019 help standardize diagnosis but are used alongside clinical judgment.

Treatment and management (quick overview)

SLE is usually managed long‑term by rheumatologists with a tailored plan based on which organs are involved.

Common components:

• Baseline: hydroxychloroquine for most patients (unless contraindicated), plus sun protection and lifestyle counseling.

• For flares or moderate disease: low‑ to medium‑dose glucocorticoids (steroids) for limited periods.

• For organ‑threatening disease (e.g., kidney, brain): immunosuppressants such as mycophenolate, azathioprine, cyclophosphamide, or biologic agents (like B‑cell–targeted therapies).

• Goal: achieve remission or low disease activity, minimize steroid exposure, prevent organ damage, and preserve quality of life.

Prognosis today

• Survival and quality of life have improved markedly over recent decades with earlier diagnosis and better therapies.

• Many people with SLE can lead active lives, but the disease still carries increased risks of organ damage, infections, cardiovascular disease, and pregnancy complications.

• Regular follow‑up and adherence to treatment are crucial to reduce flares and long‑term damage.

HTML table: quick facts about SLE

html

<table>
  <thead>
    <tr>
      <th>Aspect</th>
      <th>Key points</th>
    </tr>
  </thead>
  <tbody>
    <tr>
      <td>Definition</td>
      <td>Chronic multisystem autoimmune disease with inflammation and immune‑complex–mediated tissue damage.[web:1][web:3][web:5][web:7]</td>
    </tr>
    <tr>
      <td>Main organs affected</td>
      <td>Skin, joints, kidneys, blood, brain, lungs, heart, blood vessels.[web:1][web:3][web:7][web:8][web:10]</td>
    </tr>
    <tr>
      <td>Typical symptoms</td>
      <td>Fatigue, fever, joint pain, malar rash, photosensitivity, mouth ulcers, chest pain, swelling, neurologic symptoms.[web:1][web:3][web:7][web:8]</td>
    </tr>
    <tr>
      <td>Who is affected</td>
      <td>Predominantly women of child‑bearing age; more common and severe in certain ethnic groups.[web:3][web:5][web:7][web:9][web:10]</td>
    </tr>
    <tr>
      <td>Main lab markers</td>
      <td>ANA, anti‑dsDNA, anti‑Sm, antiphospholipid antibodies, low complement, abnormal blood counts.[web:1][web:5][web:7][web:9]</td>
    </tr>
    <tr>
      <td>Treatment goal</td>
      <td>Remission or low disease activity with minimal steroid use and prevention of organ damage.[web:4][web:5][web:9][web:10]</td>
    </tr>
    <tr>
      <td>Prognosis</td>
      <td>Much improved compared with past decades but still associated with significant morbidity and increased mortality risk.[web:1][web:4][web:7][web:9]</td>
    </tr>
  </tbody>
</table>

Bottom note

Information gathered from public forums or data available on the internet and portrayed here.

If you or someone you know has symptoms that sound like lupus, it is important to see a qualified healthcare professional; online information cannot replace an in‑person medical evaluation.